Convalife presents new dual CDK4/cyclin D1 and CDK9 inhibitors
Summary
Convalife researchers disclosed new dual CDK4/cyclin D1 and CDK9 inhibitors. The compounds are intended for cancer treatment and may also support inflammatory disorder research. The item centers on early-stage drug discovery and patent-style scientific findings rather than a commercial software release. It is relevant to the life sciences sector because it concerns pharma research and development activity.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected